Top Visited Report: Biosimilar Opportunities In An Evolving Market Available at MarketResearchReports.biz

Biosimilar Opportunities In An Evolving Market

The long awaited promise of biosimilars takes another step to fulfilment with the first approval in Europe of high-value second generation products. But what products can be expected to follow, who is developing them and what are the hot prospects?

To Read The Complete Report with  TOC:-

http://www.marketresearchreports.biz/analysis-details/biosimilar-opportunities-in-an-evolving-market 

Biosimilars: another milestone passed

At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first monoclonal antibody (mAb) therapies to reach a positive opinion following review via the EMA biosimilars regulatory pathway. This is an important event which heralds a new era of lower-cost biological therapies in Europe.

For J&J and its partners, the news is less welcome. Already under pressure from branded competitors in the TNF inhibitor market, it is no surprise that both developer and biosimilar companies will be assessing what share they may secure of its US$6.13 billion revenues.

To Buy a Copy Of This Report:-

http://www.marketresearchreports.biz/analysis/172480 

The tip of a US$41 billion iceberg

While significant for J&J, infliximab is just the tip of the iceberg when it comes to the potential for biosimilars. In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), Sanofi’s Lantus (insulin glargine), and Johnson & Johnson’s Remicade (infliximab). These products had combined global sales of US$41.4 billion in 2012. Also of significant importance to biosimilar developers, with sales of US$4.2 billion in 2012 is Amgen’s Enbrel (etanercept).

  

Contact:-

M/s  Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email:        sales@marketresearchreports.biz 

Website:     http://www.marketresearchreports.biz/ 

Blog:          http://marketsbuzz.wordpress.com/ 

MOst Popular Report: Challenges And Opportunities-In The Renal Denervation Market Available at MarketResearchReports.biz

Challenges And Opportunities-In The Renal Denervation Market

  

Hypertension: Prevalence and Significance

Hypertension is one of the most preventable causes of premature morbidity and mortality globally. It is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, peripheral vascular disease, cognitive decline, damage to retinal blood vessels and visual impairment, and premature death. Therefore, reducing hypertension can lower the incidence of these conditions, helping to improve the health of the population and reducing the high burdens that they place on global healthcare systems.

To Read The Complete Report with  TOC :

http://www.marketresearchreports.biz/analysis-details/challenges-and-opportunities-in-the-renal-denervation-market 

Renal denervation therapy involves a surgical procedure and is therefore a last resort in the treatment of hypertension. It is only considered when cheaper, simpler and potentially safer alternatives such as lifestyle modifications and the use of pharmaceuticals have failed. These patients are termed as having treatment-resistant hypertension.

Current Trends and Future Opportunities

With renal denervation technology only having been in development since the late 1990s and commercially-available since 2010, the market is in its infancy. The products remain unapproved in the US and Japan, and reimbursement is not yet widely available in other regions. Despite being an emerging market, renal denervation has sparked considerable interest due to the good safety and efficacy results it has achieved so far in helping to reduce treatment-resistant hypertension. The expectation is that renal denervation could become a multi-billion dollar market in the future. However, the success of any new medical technology is dependent on regulatory approval and reimbursement; acceptance and awareness from the medical community; and evidence of safety, efficacy and cost-effectiveness. All of these elements must be in place for the market to realise its potential.

To Buy a Copy Of This Report:-

http://www.marketresearchreports.biz/analysis/172371 

Understand the current trends and future opportunities to invest in, in this essential report, and learn about the products and technologies leading this dynamic market. Challenges and Opportunities in the Renal Denervation Market is the complete guide with all you need to know!

Contact:-

M/s  Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email:        sales@marketresearchreports.biz 

Website:    http://www.marketresearchreports.biz/ 

Blog:          http://marketsbuzz.wordpress.com/ 

Global Survey Report: World Medical Markets Fact Book 2013 Available at MarketResearchreports.biz

The World Medical Markets Fact Book 2013

Description:

The indispensable source of thousands of facts, figures and statistics for 67 medical markets worldwide!

The World Medical Markets Fact Book 2013 is the ideal companion in today’s challenging medical market environment. The need to understand world medical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive source of key market statistics is an invaluable aid for every medical device industry executive.

To Read The Complete Report with  TOC :

http://www.marketresearchreports.biz/analysis-details/the-world-medical-markets-fact-book-2013 

Proven and reliable

Published by Espicom - experts in the healthcare field for over 30 years, the Fact Book brings together a range of often difficult to source information in one single, convenient and comprehensive publication.

Key market questions answered by The World Medical Markets Fact Book 2013

·         Which country spends most on medical devices as a % of GDP?

·         How are the economic downturn and currency fluctuations affecting expenditure in key Asian markets?

·         Which medical device sectors are growing the fastest and where?

·         How does the Brazilian medical market compare with China and India in terms of total health expenditure?

·         What demographic development is affecting the market in Central and Eastern Europe?

·         What have been the key trends affecting medical technology companies in leading Latin American markets?

  

To Buy a Copy Of This Report:-

http://www.marketresearchreports.biz/analysis/172331 

  

  

Over 25,000 data points at your fingertips! Which other business reference provides…

·         Key economic, demographic and health statistics on 67 markets around the world

·         Five years of historical data for markets, GDP & healthcare spending, demographics and healthcare statistics

·         World/regional overviews plus statistics on individual countries

·         Over 500 tables and charts delivered in a single PDF report

·         PLUS an additional interactive data tool included in the price, where you can segment, compare and export the data in any way that you wish, to suit your information needs 

Contact:-

M/s  Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email:        sales@marketresearchreports.biz 

Website:    http://www.marketresearchreports.biz/ 

Blog:          http://marketsbuzz.wordpress.com/ 

Recent Research Report: World Generic Market Report 2013

Description

A complete global analysis of the prospects for markets and companies in this dynamic industry sector

To Read The Complete Report with  TOC :-

http://www.marketresearchreports.biz/analysis-details/world-generic-market-report-2013

Features and benefits of this thoroughly-researched and highly-regarded management report:

• High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your business planning and decision-making process
• Global coverage - with 74 country markets profiles: Scope opportunities for new investment or sales growth, with detailed historical data and forecasts on the leading developed economies as well as key emerging markets from Africa, the Americas, Asia, Emerging Europe, and the Middle East
• Issue driven: Understand the latest company, product, and regulatory developments
• Company Insight - with the 26 leading companies reviewed: Who’s working with whom? Who’s suing whom? Who’s up, who’s down? Assess the activities, strategies and market position of your competitors, partners and clients
• Flexible formats: Available in pdf format with online access included in the price. Cost-effective distribution licences can ensure you get the best from your investment
• Biosimilars: Coverage of the fast developing biosimilars market
• Easily understand the threats and opportunities that are shaping this rapidly evolving sector!

Industry Issues 

If the branded pharmaceutical industry was facing a patent cliff it is now teetering on the edge of it. Ironically, it is the world’s best selling drug, Lipitor, which exemplifies the trend. Despite still having patent protection, Pfizer has been unable to stem the tide of interest and pressure from a number of companies, Ranbaxy being chief amongst them. Despite pressure on prices in many markets, the generic sector continues to thrive with increased sales across the board in 2012. The maturity of the sector can also be seen in the size of the businesses: there are now 18 generic companies with revenues in excess of US$1,000 million, 6 more than in 2008/09..

Company Assessments

In recent years there has been a trend towards consolidation, both within the generics industry itself, and between the generics industry and the branded industry. This has been a trend born of necessity, reflecting both the difficult economic environment and the slowdown in development of innovative drugs. Without doubt, the most important and largest acquisition to have taken place over the last year has been the merger between Watson Pharmaceuticals and Actavis. The merger has created a company with revenues for the year ended 31st December 2012 of just over US$5.9 billion.

Market Analysis

The generic market is experiencing two opposing trends driven by the global downturn. On one hand, the use of generics is increasing due to their cost-effectiveness and adoption has accelerated in markets where branded prescribing was dominant. On the other hand, the squeeze on government spending has not left generics untouched, with many countries lowering generic prices through cuts in reimbursement rates or contract tendering with a resultant squeeze on margins.

Industry consolidation, new market opportunities, the latest on biosimilars plus much, much more!

This leading report, now in its 11th year of publication, draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues. This extensive data set is interpreted and evaluated by the editors to provide a complete and compelling review of the whole sector.

To Buy a Copy Of This Report:-

      http://www.marketresearchreports.biz/analysis/170302

Key facts, issues and questions

• Which branded companies are taking an increased interest in the dynamic generics market?
• How are generics companies faring in the recession?
• Which companies are involved in the latest legal challenges and litigation?
• Biosimilars get ever closer – what are the latest regulatory updates?
• Which country markets have experienced the largest growth in 2012 and which are forecast to be the fastest growers?
• Negative perceptions of generic drug quality – which markets are most exposed?
• Pricing pressures – which markets are facing the greatest pressures on pricing from the government?
• State support for local production – which markets are set to benefit from increased government support?       

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog:  http://marketsbuzz.wordpress.com/

Silent Killer: Recent Advances in Cardiovascular Disease by marketresearchreport.biz

Here are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace.

To Read The Complete Report with  TOC :-

http://www.marketresearchreports.biz/analysis-details/the-silent-killer-recent-advances-in-cardiovascular-disease

Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered.

This report provides you with a systematic appraisal into the current and future CV market, including...

A detailed review of the leading brands and how they are being positioned in the market, in addition to the potential impact of generics

• Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established
• Review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered
• Analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested
• Antilipidemics

The lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) has been shown to reduce the chance of a heart attack and death in people who have an elevated risk of developing heart disease or who already have heart disease. Several drug classes are currently available to treat a range of lipid disorders; each has a different mechanism of action, safety profile and impact on blood lipid profiles to different degrees.

To Buy a Copy Of This Report:-

        http://www.marketresearchreports.biz/analysis/170303

Key drugs covered by the report include

• Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc...
• Recent generics - Atorvastatin, etc...
• Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc...
• Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr Reddy), etc...
• Long shots - ALN PCS (Alnylam/The Medicine Company), etc...
• Just some of the key questions answered include

• Why are statins the gold stand in lipid lowering therapies and which is the most effective at lowering LDL-C?
• Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market?
• Why are PCSK9 inhibitors important to cardiologists and which drugs are leading the field?
• Kynamro approved in the US but not in Europe… what next?
• What new HDL-C modulating therapies are in development?
• What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog:  http://marketsbuzz.wordpress.com/